- Home
- NEN vs PLX Comparison
NEN vs PLX Comparison
Compare NEN & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
NEN
New England Realty Associates Limited Partnership Depositary Receipts Evidencing Units of Limited Partnership
Current Price
Current Price
Company Overview
Basic Information| Metric | NEN | PLX |
|---|---|---|
| Founded | 1977 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Building operators | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 227.9M | 230.0M |
| IPO Year | 1995 | 1996 |
Fundamental Metrics
Financial Performance| Metric | NEN | PLX |
|---|---|---|
| Price | $62.26 | $2.89 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | 1.5K | ★ 1.4M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 7.71% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $80,532,550.00 | $53,399,000.00 |
| Revenue This Year | N/A | $9.67 |
| Revenue Next Year | N/A | $23.86 |
| P/E Ratio | $19.68 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $62.00 | $1.34 |
| 52 Week High | $84.00 | $3.19 |
Technical Indicators
Market Signals| Indicator | NEN | PLX |
|---|---|---|
| Relative Strength Index (RSI) | 47.35 | 54.01 |
| Support Level | $62.05 | $1.39 |
| Resistance Level | $66.30 | $3.11 |
| Average True Range (ATR) | 0.63 | 0.16 |
| MACD | 0.17 | -0.06 |
| Stochastic Oscillator | 65.00 | 45.45 |
Price Performance
Historical ComparisonAbout NEN New England Realty Associates Limited Partnership Depositary Receipts Evidencing Units of Limited Partnership
New England Realty Associates LP is engaged in the business of acquiring, developing, holding for investment, operating and selling real estate. The Partnership owns and operates various residential apartments, condominium units and commercial properties located in Massachusetts and New Hampshire. The company generates revenue from rental income from residential and commercial properties recognized over the term of the related lease. The long-term goals of the Partnership are to manage, rent and improve its properties and to acquire additional properties with income and capital appreciation potential as suitable opportunities arise.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.